Topical Lomefloxacin 0.3% Twice Daily versus Tobramycin 0.3% in Acute Bacterial Conjunctivitis: A Multicenter Double-Blind Phase III Study

• Published in: Ophthalmologica (Basel) Vol. 213; no. 4; pp. 250 - 257
• Main Authors: Gallenga, P.E., Lobefalo, L., Colangelo, L., Della Loggia, G., Orzalesi, N., Velati, P., Bujtar, E., Ponte, F., Damiani, S., Bucci, M.G., Bonini, S., Curatola, M.R., Palma, L.A., Bonomi, L., Tomazzoli Gerosa, L., Pagliarusco, A., Milan, E., Jauch, A.
• Format: Journal Article
• Language: English
• Published: Basel, Switzerland Karger 01.07.1999; S. Karger AG
• Subjects: Acute Disease; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents - administration & dosage; Anti-Bacterial Agents - therapeutic use; Anti-Infective Agents - administration & dosage; Anti-Infective Agents - therapeutic use; Antibacterial agents; Antibiotics. Antiinfectious agents. Antiparasitic agents; Bacteria; Bacteria - drug effects; Bacteria - growth & development; Bacteria - isolation & purification; Biological and medical sciences; Child; Colony Count, Microbial; Conjunctiva - microbiology; Conjunctivitis, Bacterial - drug therapy; Conjunctivitis, Bacterial - microbiology; Double-Blind Method; Female; Fluoroquinolones; Follow-Up Studies; Haemophilus Infections - drug therapy; Haemophilus Infections - microbiology; Humans; Male; Medical sciences; Middle Aged; Ophthalmic Solutions; Original Paper · Travail original · Originalarbeit; Pharmacology. Drug treatments; Prospective Studies; Quinolones - administration & dosage; Quinolones - therapeutic use; Staphylococcal Infections - drug therapy; Staphylococcal Infections - microbiology; Streptococcal Infections - drug therapy; Streptococcal Infections - microbiology; Tobramycin - administration & dosage; Tobramycin - therapeutic use; Treatment Outcome; Lomefloxacin 0.3; Bacterial resistance; Acute bacterial conjunctivitis; Tobramycin 0.3; Human; Acute; Treatment efficiency; Lomefloxacin; Conjunctiva disease; Conjunctivitis; Infection; Eye drop; Local administration; Eye disease; Antibiotic; Chemotherapy; Fluoroquinolone derivatives; Treatment; Aminoglycoside; Bacteriosis; Tobramycin; Antibacterial agent; Comparative study; Quinolone derivatives
• ISSN: 0030-3755; 1423-0267
• DOI: 10.1159/000027430

Aims/Background: To evaluate in a double-masked comparative, prospective, randomized multicenter trial the efficacy of lomefloxacin 0.3% eye drops twice daily and of tobramycin eye drops 4 times daily in patients with acute bacterial conjunctivitis. Methods: Ninety-nine subjects were enrolled: 50 were treated with lomefloxacin 0.3% eye drops twice daily and 49 with tobramycin 0.3% eye drops 4 times daily. In all patients, conjunctival swabbing and assessment of objective signs and of subjective symptoms were performed. Results: There was no statistical difference for any individual sign or symptom or for the sum score of either key or other signs and symptoms at any of the examination days. The sum score of both key and other signs and symptoms decreased in both groups at day 3–4 as compared to baseline values (p < 0.0001). The decrease in both these scores continued significantly from day 3–4 to day 7–8 (p < 0.05) and was similar in the two treatment groups (p > 0.4). The lowest resistance rate was seen in lome-floxacin (3.5%) and in neomycin (7.0%), while tobramycin showed resistance in 10 out of 88 resistance strains (11.4%). Conclusion: Both lomefloxacin 0.3% twice daily and tobramycin 0.3% administered 4 times daily were well tolerated and showed a high degree of clinical and microbiological efficacy in the treatment of acute bacterial conjunctivitis. Lomefloxacin caused less resistance than other antibiotics evaluated.